Phase 2 N=33 Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury
ISCHEMIC CARDIOMYOPATHY
Primary: Infarct Size of MEMRI Versus DEMRI Scans — 12.2; 18.9 percentage of left ventricle — p=0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1 Effects of Leptin Replacement in Children
Obesity · Metabolic Syndrome · Diabetes
Primary: Weight — NA lbs
Phase 2 N=3 Effects of Human Leptin Replacement
Obesity · Metabolic Syndrome · Diabetes
Primary: Change in Weight — NA lbs
Phase 2 N=47 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Chondrosarcoma · Metastatic Chondrosarcoma
Primary: Disease Control at Week 16 — 43 Percentage of CR+PR+SD
Phase 2 N=360 A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
Alzheimer's Disease
Primary: Percentage of Participants With Adverse Events (AEs) — 89.4; 90.5; 96.0; 87.9 percentage of participants
Phase 2 N=20 Trametinib With GSK2141795 in BRAF Wild-type Melanoma
Melanoma
Primary: Objective Response Rate (ORR) — 5; 4 Participants
Phase 2 N=5 S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOX — 0; 3; 3 ug/kg
Phase 2 N=14 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Neoplasms · Triple Negative Breast Cancer · Ovarian Cancer
Primary: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs) — 1; 1 Participants
Phase 2 N=120 Metformin and Muscle in Insulin-resistant Older Veterans
Prediabetes
Primary: Change in Total Lean Mass From Baseline — 322.8; 697.6; 392.4; 548.0 grams lean mass — p=0.45
Phase 2 N=228 LACTIN-V Study for Recurrent Bacterial Vaginosis
Bacterial Vaginosis
Primary: The Proportion of Participants Reporting Product-related Adverse Events (AEs) and Serious Adverse Events (SAEs) in Each Study Arm. — 0.11; 0.07 proportion of…
Phase 2 N=62 Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?
Weight Loss
Primary: Change From Baseline in Insulin Sensitivity at Week 12 Via Oral Glucose Tolerance Test — 6.9; 11.1; 5.5; 6.5 mU/L
Phase 2 N=41 NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
Phase 2 N=33 Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
Chronic Lymphocytic Leukemia
Primary: Improvement in Quality of Remission: Number of Participants With Response Versus No Response by NCI Working Group Criteria Disease Status Change at Start/End of…
Phase 2 N=58 Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
Stomach Cancer · Gastric Cancer
Primary: Complete Pathologic Response Rate — 14 percentage of participants
Phase 2 N=26 Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants